Acute Management of Upper Gastrointestinal Bleeding
For nonvariceal UGIB, initiate IV pantoprazole 80 mg bolus followed by 8 mg/hour continuous infusion for 72 hours after endoscopic hemostasis; for variceal bleeding in cirrhosis, start octreotide 50 mcg IV bolus then 50 mcg/hour infusion for 3-5 days plus prophylactic antibiotics (ceftriaxone 1 g IV daily for 7 days preferred, or norfloxacin 400 mg PO BID if oral intake possible). 12
Nonvariceal Upper GI Bleeding (Peptic Ulcer Disease)
Pre-Endoscopic Pharmacotherapy
Proton Pump Inhibitor: Administer IV PPI before endoscopy 1
- Pantoprazole dosing: 40 mg IV once daily is FDA-approved for GERD with erosive esophagitis 33
- Critical caveat: The FDA label explicitly states that pantoprazole 40 mg once daily "does not raise gastric pH to levels sufficient to contribute to the treatment of such life-threatening conditions" as acute UGIB 33
Erythromycin: Consider as prokinetic agent to improve endoscopic visualization
Do NOT use:
Post-Endoscopic Management (High-Risk Stigmata)
For patients with high-risk bleeding stigmata (Forrest Ia, Ib, IIa) who undergo successful endoscopic therapy:
IV PPI regimen: 80 mg bolus followed by 8 mg/hour continuous infusion for 72 hours 1
- This is a strong recommendation with moderate-quality evidence 1
- Alternative: Twice-daily IV or oral PPI can be considered, though continuous infusion is preferred
Transition to oral therapy: After 72 hours, switch to oral PPI twice daily for 14 days, then once daily 1
Important distinction: The guideline-recommended high-dose regimen (80 mg bolus + 8 mg/hour infusion) differs from the FDA-approved dosing (40 mg once daily), reflecting that the FDA label acknowledges inadequacy of standard dosing for life-threatening bleeds 33.
Variceal Upper GI Bleeding
Immediate Pharmacotherapy (Start Before Endoscopy)
Vasoactive medications - initiate as soon as variceal hemorrhage is suspected:
Octreotide (preferred in many centers): 50 mcg IV bolus, then 50 mcg/hour continuous infusion for 3-5 days 24
- More effective than vasopressin with fewer side effects 4
Terlipressin (alternative): 2 mg IV every 4 hours for first 24 hours, then 2 mg every 6 hours 5
Prophylactic Antibiotics (Critical Component)
All patients with cirrhosis and GI bleeding require antibiotic prophylaxis - this is a strong recommendation with high-quality evidence 2:
First-line: Ceftriaxone 1 g IV daily for up to 7 days 2
- Preferred in advanced cirrhosis
- Preferred in centers with high quinolone-resistant organisms
Alternative: Norfloxacin 400 mg PO twice daily for 7 days (if oral intake possible) 2
- Or IV ciprofloxacin if oral not feasible
Important controversy: Recent 2025 meta-analysis questions the mortality benefit of antibiotic prophylaxis, showing 97.3% probability of noninferiority for shorter/no antibiotic duration 7. However, current guidelines still strongly recommend prophylaxis 2, and this remains standard of care until higher-quality RCTs are available.
Endoscopic Timing
- Perform endoscopy within 12 hours for suspected variceal bleeding 2
- For nonvariceal bleeding, perform within 24 hours (not urgent <12 hours) 8
Risk Stratification
- Glasgow-Blatchford Score ≤1: Safe for outpatient management with outpatient endoscopy 8
- Patients requiring intervention should undergo early endoscopy
Transfusion Strategy
- Restrictive approach: Target hemoglobin <7 g/dL unless cardiovascular disease present 2
Antiplatelet/Anticoagulation Management
- Low-dose aspirin for secondary cardiovascular prophylaxis: Do NOT interrupt; if interrupted, restart within 3-5 days 8
- Anticoagulation: Resume as soon as bleeding controlled, preferably within or soon after 7 days based on thromboembolic risk 8
Common Pitfalls
Using standard-dose PPI (40 mg once daily) for high-risk peptic ulcer bleeding: The FDA label itself acknowledges this is insufficient 33. Use high-dose regimen (80 mg bolus + 8 mg/hour infusion).
Delaying vasoactive medications in suspected variceal bleeding: Start octreotide or terlipressin immediately, before endoscopy 2.
Omitting antibiotics in cirrhotic patients: This is a strong guideline recommendation despite recent controversy 2.
Using octreotide for peptic ulcer disease: Not indicated - only for variceal bleeding 1.
Continuing IV PPI indefinitely after endoscopy shows low-risk lesions: Transition to oral therapy and adjust duration based on underlying cause 1.